HLS Therapeutics Inc (HLS.TO)
3.66
+0.06
(+1.67%)
CAD |
TSX |
Sep 27, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 116.36M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -28.93% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.469 |
| Price to Book Value | 1.028 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.9968 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 87.57% |
Profile
| HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world. |
| URL | https://www.hlstherapeutics.com |
| Investor Relations URL | https://hlstherapeutics.investorroom.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 08, 2024 (est.) |
| Last Earnings Release | Aug. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 27, 2023 |
Ratings
Profile
| HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world. |
| URL | https://www.hlstherapeutics.com |
| Investor Relations URL | https://hlstherapeutics.investorroom.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 08, 2024 (est.) |
| Last Earnings Release | Aug. 08, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 27, 2023 |